Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
OSE Pharma
Research
ASCO: BI, OSE report promising early results for I-O drug
BI and OSE unveiled data from a phase 1 trial of BI 765063, a SIRP-alpha inhibitor, reporting that 45% of evaluable patients benefited.
Arlene Weintraub
May 21, 2021 10:05am
OSE details strategy targeting 'don't eat me' signal in cancer
Nov 16, 2020 8:53am
OSE, MSK ally to advance anti-CD127 NSCLC candidate
Jun 13, 2017 5:51am
